Real Life Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-07

Study Completion Date

2025-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of patient's proportion, whose management care has been modified at least once and specially by Moovcare® Lung application at 12 and 24 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare®

NCT05011890

Lung Cancer Neoplasms, Lung Neoplasms, Pulmonary +3 more

COMPLETED NA

Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery

NCT06483698

Lung Cancer

RECRUITING

The Construction and Clinical Application of an Integrated Perioperative Management System for Lung Cancer Based on Wearable Devices and Intelligent Platforms

NCT07310056

Non-Small Cell Lung Cancer (NSCLC) Rehabilitation Thoracic Surgery +1 more

NOT_YET_RECRUITING NA

Exercise as Maintenance Therapy in Advanced Lung Cancer

NCT06513663

Lung Cancer Non Small Cell Lung Cancer Metastatic Lung Cancer

RECRUITING NA

Computer-Generated Quality of Life Assessment Program for Advanced Non-Small Cell Lung Cancer Patients (LUNL2)

NCT01337102

Non Small Cell Lung Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary objective of the study:

The primary objective is a clinical one and is to evaluate the proportion of patients, whose management care has been modified at least once and specially by Moovcare® Lung application at 12 and 24 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients treated for their lung cancer and Moovcare® Lung follow-up.

Group Type OTHER

Patients treated for their lung cancer.

Intervention Type DEVICE

In addition to the weekly Moovcare® Lung follow-up, patients will benefit from standard oncological follow-up at the discretion of their oncologist according to standard recommendations for 2 years. Questionnaires will be completed at different times as mentioned below on the global study scheme and Flowchart.

In an active treatment situation, the pace of consultations will be adapted to the pace of treatment administration, according to standard recommendations. It may be lengthened in the absence of a clinical application or biological alert at the discretion of the investigator.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patients treated for their lung cancer.

In addition to the weekly Moovcare® Lung follow-up, patients will benefit from standard oncological follow-up at the discretion of their oncologist according to standard recommendations for 2 years. Questionnaires will be completed at different times as mentioned below on the global study scheme and Flowchart.

In an active treatment situation, the pace of consultations will be adapted to the pace of treatment administration, according to standard recommendations. It may be lengthened in the absence of a clinical application or biological alert at the discretion of the investigator.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient with lung cancer at any diagnostic stage and histology.
2. Patient willing to use the follow-up setting with Moovcare® Lung apps.
3. Age ≥ 18 years.
4. Patient received anti-cancer treatment (surgery, chemotherapy, radiation (stereotaxy or not) or radio-chemotherapy association ended less than 12 weeks (Cohort 1 post-treatment); or during maintenance treatment or consolidation by chemotherapy or targeted therapy, or by immunotherapy initiated less than 12 weeks (Cohort 2 during treatment).
5. Imaging tumor evaluation less than 12 weeks showing disease control (response or stability according to RECIST 1.1 criteria).
6. Patient with symptomatic score on Moovcare® Lung apps less than 7.
7. Patient (or relatives) with internet access, a personnal e-mail box and a smartphone.
8. Patient with social security affiliation.
9. Signed informed consent form.

Exclusion Criteria

1. Patient with progression after the first evaluation of initial treatment.
2. Pregnancy and breast-feeding.
3. Patient under tutorship or guardianship.
4. Dementia, mental alteration or psychiatric pathology influencing patient consent procedure and/or protocol observance and study follow-up.
5. Patient enable to protocol follow-up for psychological, social, familial or geographical reasons.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No